PD-1 is in full bloom, and the age of tumor immunity is coming!

PD-1 class of drugs refers to different from traditional chemotherapy and targeted therapy, mainly by overcoming immunosuppression in the patient's body, reactivation of the patient's own immune cells to kill tumors.
as a brand-new concept of anti-tumor treatment, PD-1 is now in full bloom, which has attracted a lot of money and scientists into the study of tumor immunity, the era of tumor immunity is coming.
PD-1 market will be about US$22 billion in 2019, and China's PD-1/PD-L1 inhibitor market is expected to reach RMB13.2 billion in 2020, RMB66.4 billion in 2023 and RMB98.8 billion in 2030, according to the data.
, a total of 4 domestic enterprises PD-1 products listed.
include Xinda Bio's Xindili monoanti-anti-injection, Beji Shenzhou's Tyrelli-Pearl monoanti, Hengrui Pharmaceutical's Karelli-Pearl monoanti and Regency's Ripley monoanti.
, Thyda Bio's Xindili monoanti-injection is the first PD-1 product to be included in the national health insurance catalog.
first half of this year, Xindili mono-anti-injection revenue of 920 million yuan, close to Thyme Bio's full-year 2019 revenue.
report that Dabershu's sales this year are expected to sprint by 2 billion yuan.
In addition to the bright performance, Xindili monoanti also outstanding performance in large-scale adaptive disorders, including non-scale NSCLC first-line, scaly NSCLC first-line has submitted a listing application, liver cancer first line is expected to be submitted in late 2020 or early 2021 listing applications, stomach cancer, esophageal cancer Phase III clinical entry group is about to be completed.
, Xinda Bio is currently layout targets such as CTLA-4, CD47 Series, LAG3 Series, TIGIT, OX40 Series, etc.
promotes the internationalization of Cynda Bio products through strategic partnerships with a number of international biopharmaceutical companies, including Lilly Pharmaceuticals, Roche Pharmaceuticals, Adimab, Incyte, Alector, MD Anderson Cancer Center and Hanmi Korea.
The PD-1 product of Baiji Shenzhou has two currently approved adaptive disorders for Reilly Juju, namely, relapsed or refractic classic Hodgkin lymphoma after at least second-line system chemotherapy, and local late or metastatic urethra cancer.
the product commercialized in early March 2020, generating sales of $49.94 million ($339 million) in the first half of the year over a period of about four months.
Hengrui Medicine's Karelli Zhudan resistance has been officially approved by the State Drug Administration for at least after the second-line system treatment of recurrence or refractory classic Hodgkin's lymphoma, hepatocellular carcinoma, lung cancer and esophageal cancer and other fields of treatment.
addition, the drug showed good anti-tumor potential in malignant tumors such as nasopharyngeal cancer, stomach cancer and gastroesophageal junction cancer.
first half of this year, the product sales of about 2 billion yuan in size.
's other domestic PD-1 drug is Theripri monoanti, which broke out on December 17, 2018, becoming the first approved domestic PD-1 monoantigen for the treatment of local progression or metastasis melanoma after previous standard treatment failures.
the current species in the field of lung cancer exploration has also achieved some results.
Overall, of the four PD-1 products, Xinda Bio occupies an advantageous position in the oncology drug research and development pipeline, and with the continued release of DD-1 monoanti (PD-1 monoanti) after the inclusion of health insurance, the market generally expects the future as more adaptive disorders become popular, the increase in sales volume is basically predictable.
, Xinda Bio in the future research and development of many projects are also in the domestic related manufacturers in the dominant position.